| This week's sponsor is Premier Research. | |  | Heartbreak No Longer: Winning the Battle Against Psoriasis
New treatments have broken the cycle of despair for people with severe psoriasis. Learn about the latest advances — and what to expect next — at our March 29 webinar. Register today. Premier Research. It's what we do. Best. |
Featured Story Monday, March 13, 2017  President Donald Trump has chosen Scott Gottlieb to run the FDA. Gottlieb has a history of calling for faster approvals, greater regulatory transparency and a realignment of the balance of power between FDA and doctors, but as an industry insider is seen as a safer pair of hands than some of the other mooted candidates.
| This week's sponsor is Trianni. | |  | |
Top Stories Monday, March 13, 2017 Last year, ex-Pfizer exec Geno Germano joined synthetic biology firm Intrexon as president and CEO-in-waiting, intent on helping the company push forward its cell and gene therapies. Fast-forward a few months, and Germano is leaving, prompted by a restructuring that has stripped those health-related programs from beneath him. Monday, March 13, 2017 Karyopharm has seen studies for its big hope selinexor placed on a partial clinical hold, meaning it can no longer recruit new patients, over the FDA’s demands for more safety details, but the company insists this is all down to paperwork errors. Monday, March 13, 2017 Heptares Therapeutics has struck a pain drug R&D pact with Daiichi Sankyo. The agreement will see Heptares apply the G protein-coupled receptor and structure-based drug design skills that have landed it deals with Allergan, AstraZeneca and Pfizer to the discovery of small molecules that hit a pain target. Friday, March 10, 2017 Checkpoint inhibitors like Merck’s Keytruda (pembrolizumab) are designed to stimulate the immune system’s T cells to recognize and attack cancer cells. Problem is, they don’t work for many patients, and no one has been able to pinpoint exactly why. Now, scientists at Emory say they’ve found a clue. Monday, March 13, 2017 Is Spinraza the next Sovaldi? That’s the question on the minds of health insurers, analysts and investors as Biogen launches Spinraza (nusinersen), its highly anticipated spinal muscular atrophy drug. The latest health industry player to raise a red flag about Spinraza’s price is Molina Healthcare, which warned in its recent annual report that it didn’t factor the drug into its expectations for this year and that it might affect earnings. | This week's sponsor is Fisher Clinical Services. | |  | |
| | | Beset by problems, Cempra asked Morgan Stanley to help weigh up its corporate options but has kept mum on the details. Statement Heat Biologics hit an efficacy endpoint in phase 1b test of its HS-110 candidate in combination with Bristol-Myers Squibb’s anti-PD-1 Opdivo in lung cancer, as it plans to move on to phase 2. Release Agios gets $8 million upfront from partner Celgene for an MTAP pathway research program in certain cancers, with more biobucks lined up weighted to future development. Statement | |
|
Resources Sponsored By: Veeva This white paper focuses on engaging healthcare stakeholders effectively while integrating your medical and commercial teams. Presented By: Veeva Share your thoughts on the life sciences industry’s progress in reducing system and process complexity to improve study execution. The first 50 qualified respondents will receive a $10 Amazon gift card, as well as a $10 donation made to Doctors Without Borders in their name. Finish the survey today! |
|
